GlobalData on MSN6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
BioPharma Dive6d
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
FiercePharma5d
AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
BioSpace3d
AstraZeneca, Amgen Claim Late-Stage Win in Chronic Rhinosinusitis but Analyst Flags ‘Regulatory Risk’
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
Zacks.com on MSN1d
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
Alliance revenues included $361 million from Daiichi Sankyo for Enhertu and $123 million of AstraZeneca’s share of gross ...
AstraZeneca’s Tezspire Shows Promise in Phase III Trial
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...
London South East6d
Tezspire nasal polyps trial met primary endpoints
Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps Tezspire demonstrated a statistically significant and clinically ...
Morningstar6d
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal ...
Yahoo Finance6d
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that ...
Morningstar6d
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo Positive high-level results from the ...